434 related articles for article (PubMed ID: 22967287)
1. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.
Danhier F; Le Breton A; Préat V
Mol Pharm; 2012 Nov; 9(11):2961-73. PubMed ID: 22967287
[TBL] [Abstract][Full Text] [Related]
2. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
3. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3.
Yu YP; Wang Q; Liu YC; Xie Y
Biomaterials; 2014 Feb; 35(5):1667-75. PubMed ID: 24268666
[TBL] [Abstract][Full Text] [Related]
5. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
6. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
Dijkgraaf I; Kruijtzer JA; Frielink C; Soede AC; Hilbers HW; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
Nucl Med Biol; 2006 Nov; 33(8):953-61. PubMed ID: 17127167
[TBL] [Abstract][Full Text] [Related]
8. Molecular Imaging of Breast Cancer: Role of RGD Peptides.
Chakravarty R; Chakraborty S; Dash A
Mini Rev Med Chem; 2015; 15(13):1073-94. PubMed ID: 26349490
[TBL] [Abstract][Full Text] [Related]
9. RGD peptide-based non-viral gene delivery vectors targeting integrin α
Fu S; Xu X; Ma Y; Zhang S; Zhang S
J Drug Target; 2019 Jan; 27(1):1-11. PubMed ID: 29564914
[TBL] [Abstract][Full Text] [Related]
10. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin.
Choi Y; Kim E; Lee Y; Han MH; Kang IC
Proteomics; 2010 Jan; 10(1):72-80. PubMed ID: 19882657
[TBL] [Abstract][Full Text] [Related]
11. Design of integrin α
Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
[TBL] [Abstract][Full Text] [Related]
12. An Overview of Radiolabeled RGD Peptides for Theranostic Applications.
Badipa F; Alirezapour B; Yousefnia H
Curr Radiopharm; 2023; 16(2):107-122. PubMed ID: 36503458
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.
Liu S
Mol Pharm; 2006; 3(5):472-87. PubMed ID: 17009846
[TBL] [Abstract][Full Text] [Related]
14. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
15. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
16. Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.
Ahmadi M; Sancey L; Briat A; Riou L; Boturyn D; Dumy P; Fagret D; Ghezzi C; Vuillez JP
Cancer Biother Radiopharm; 2008 Dec; 23(6):691-700. PubMed ID: 19111043
[TBL] [Abstract][Full Text] [Related]
17. [⁶⁸Ga]NS₃-RGD and [⁶⁸Ga] Oxo-DO3A-RGD for imaging α(v)β₃ integrin expression: synthesis, evaluation, and comparison.
Knetsch PA; Petrik M; Rangger C; Seidel G; Pietzsch HJ; Virgolini I; Decristoforo C; Haubner R
Nucl Med Biol; 2013 Jan; 40(1):65-72. PubMed ID: 23102540
[TBL] [Abstract][Full Text] [Related]
18. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.
Temming K; Schiffelers RM; Molema G; Kok RJ
Drug Resist Updat; 2005 Dec; 8(6):381-402. PubMed ID: 16309948
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.
Ryppa C; Mann-Steinberg H; Biniossek ML; Satchi-Fainaro R; Kratz F
Int J Pharm; 2009 Feb; 368(1-2):89-97. PubMed ID: 18992308
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted PET tracers.
Tateishi U; Oka T; Inoue T
Curr Med Chem; 2012; 19(20):3301-9. PubMed ID: 22664242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
